CRISPR工程化CAR19通用T细胞治疗儿童难治性B细胞白血病的1期临床试验
该1期开放标签非随机临床试验评估了CRISPR-Cas9多重编辑TRAC和CD52的TT52CAR19通用T细胞,治疗6例复发/难治性CD19阳性B细胞急性淋巴细胞白血病儿童(NCT04557436)。清淋后单次输注0.8×10^6至2.0×10^6个CAR19 T细胞/kg,无即刻毒性,主要安全性目标达成。6例中4例出现细胞扩增并达到流式细胞术缓解后桥接异基因造血干细胞移植;2例需生物干预治疗II级细胞因子释放综合征,1例出现短暂IV级神经毒性,1例发生皮肤GVHD且移植预处理后消退。
要点
- 6例复发/难治性CD19阳性B-ALL患儿接受TT52CAR19通用T细胞单次输注,剂量0.8×10^6至2.0×10^6 CAR19 T细胞/kg,无即刻毒性。
- 6例中4例出现细胞扩增、达到流式细胞术缓解并接受异基因造血干细胞移植。
- 2例需生物干预治疗II级细胞因子释放综合征,1例短暂IV级神经毒性,1例皮肤GVHD移植预处理后消退。
核心结论
- 该研究证明CRISPR工程化免疫疗法具有可行性、安全性和治疗潜力。
研究设计与样本
- 1期、开放标签、非随机临床试验(NCT04557436)。
- 采用CRISPR-Cas9编辑,将CAR表达与TRAC和CD52的多重DNA编辑通过自复制CRISPR guide RNA表达盒整合至CAR19慢病毒载体3‘长末端重复序列而实现。
- 生成并冻存三批TT52CAR19 T细胞库。
- 治疗6例复发/难治性CD19阳性B细胞急性淋巴细胞白血病儿童。
- 清淋方案包括氟达拉滨、环磷酰胺和阿仑单抗,随后单次输注0.8×10^6至2.0×10^6个CAR19 T细胞/kg。
主要发现
- 6例输注TT52CAR19 T细胞的患者中4例出现细胞扩增、达到流式细胞术缓解,随后接受异基因造血干细胞移植。
- 2例患者因II级细胞因子释放综合征需要生物干预。
- 1例患者出现短暂IV级神经毒性。
- 1例患者发生皮肤GVHD,移植预处理后消退。
- 其他并发症在预期范围内,主要安全性目标达成。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genome editing of allogeneic T cells can provide "off-the-shelf" alternatives to autologous chimeric antigen receptor (CAR) T cell therapies. Disruption of T cell receptor α chain (TRAC) to prevent graft-versus-host disease (GVHD) and removal of CD52 (cluster of differentiation 52) for a survival advantage in the presence of alemtuzumab have previously been investigated using transcription activator-like effector nuclease (TALEN)-mediated knockout. Here, we deployed next-generation CRISPR-Cas9 editing and linked CAR expression to multiplexed DNA editing of TRAC and CD52 through incorporation of self-duplicating CRISPR guide RNA expression cassettes within the 3' long terminal repeat of a CAR19 lentiviral vector. Three cell banks of TT52CAR19 T cells were generated and cryopreserved. A phase 1, open-label, non-randomized clinical trial was conducted and treated six children with relapsed/refractory CD19-positive B cell acute lymphoblastic leukemia (B-ALL) (NCT04557436). Lymphodepletion included fludarabine, cyclophosphamide, and alemtuzumab and was followed by a single infusion of 0.8 × 106 to 2.0 × 106 CAR19 T cells per kilogram with no immediate toxicities. Four of six patients infused with TT52CAR19 T cells exhibited cell expansion, achieved flow cytometric remission, and then proceeded to receive allogeneic stem cell transplantation. Two patients required biological intervention for grade II cytokine release syndrome, one patient developed transient grade IV neurotoxicity, and one patient developed skin GVHD, which resolved after transplant conditioning. Other complications were within expectations, and primary safety objectives were met. This study provides a demonstration of the feasibility, safety, and therapeutic potential of CRISPR-engineered immunotherapy.
引用
- Ottaviano G, Georgiadis C, Gkazi SA, et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. 2022. PMID: 36288281. doi:10.1126/scitranslmed.abq3010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。